human embryonic stem cell derived retinal pigmented epithelial cells

Cell therapyexperimental

Clinical trial activity

5 trials · 7 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Jun 1, 2015 (NCT01691261)

Timeline

2010s

  1. Jan 1, 2015

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • RetinaTissue restoration

    tissue restoration - retina

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • embryonic stem cell-derived retinal pigment epithelial cells
  • human embryonic stem cell derived retinal pigmented epithelial
  • human embryonic stem cell derived retinal pigmented epithelial cells
  • human embryonic stem cell derived retinal pigmented epithelial cells
  • human embryonic stem cell derived retinal pigment epithelium (rpe) living tissue equivalent

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03963154Phase 1/Phase 2 (Phase 2)Jul 15, 2019Centre d'Etude des Cellules Souches
NCT03944239Phase 1Jun 30, 2019Capital Medical University, Chinese Academy of Medical Sciences
NCT03167203Phase 1/Phase 2 (Phase 2)Jun 1, 2017Astellas
NCT03305029Phase 1May 31, 2016Cha Medical University
NCT01691261Phase 1Jun 1, 2015Pfizer, University of London
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (7)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AstellasFor profit1112017
Capital Medical UniversityAcademic/Hospital1012019
Centre d'Etude des Cellules SouchesAcademic/Hospital1112019
Cha Medical UniversityAcademic/Hospital1112016
Chinese Academy of Medical SciencesAcademic/Hospital1112019
PfizerFor profit1112015
University of LondonAcademic/Hospital1012015
7 organizations
Page 1 / 1